{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:10Z","timestamp":1791478210753,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH123396"],"award-info":[{"award-number":["R01 MH123396"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Transitioning from oral to injectable HIV therapy raises unique considerations. We examined the scope and types of questions that people with HIV (PWH) raised about long-acting cabotegravir and rilpivirine (LA-CAB\/RPV). We conducted semi-structured interviews with patients at four urban HIV clinics in San Francisco, Chicago, and Atlanta (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009131). Two cross-sectional samples were recruited during August 2020 to May 2023: (1) pre-implementation, prior to widespread clinical availability (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200972); and (2) early adopters of LA-CAB\/RPV (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200959). Each dataset was analyzed separately and comparatively using thematic analysis. Participants were 65% male, 45% Black and 27% Latine with median age of 46 years. Questions clustered into four domains: (1) potential side effects; (2) effectiveness; (3) injection visit logistics; and (4) comparison to other injectable medications. Early adopters emphasized the importance of cultivating broader awareness about LA-CAB\/RPV. Findings highlight the need for clear, patient-centered information across multiple domains to support informed decisions about LA-CAB\/RPV initiation.\n                  <\/jats:p>","DOI":"10.1007\/s10461-026-05311-2","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:52:13Z","timestamp":1791474733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What Do People with HIV Want to Know About Long-Acting Injectable Cabotegravir\/Rilpivirine?"],"prefix":"10.1007","author":[{"given":"Alicia","family":"Dawdani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylin V.","family":"Dance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9651-254X","authenticated-orcid":false,"given":"Moira C.","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier A.","family":"Erguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rey","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami Diaz","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyasha","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Balter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory O.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sauceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren F.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Colasanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Koester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina A.","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"1","key":"5311_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1023\/A:1022513507669","volume":"7","author":"RH Remien","year":"2003","unstructured":"Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to Medication Treatment: A Qualitative Study of Facilitators and Barriers Among a Diverse Sample of HIV\u2009+\u2009Men and Women in Four U.S. Cities. AIDS Behav. 2003;7(1):61\u201372. https:\/\/doi.org\/10.1023\/A:1022513507669.","journal-title":"AIDS Behav"},{"issue":"7","key":"5311_CR2","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s10461-024-04315-0","volume":"28","author":"XA Erguera","year":"2024","unstructured":"Erguera XA, Koester KA, Diaz Tsuzuki M, Dance KV, Flores R, Kerman J, et al. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States. AIDS Behav. 2024;28(7):2226\u201338. https:\/\/doi.org\/10.1007\/s10461-024-04315-0.","journal-title":"AIDS Behav"},{"issue":"11","key":"5311_CR3","doi-asserted-by":"publisher","first-page":"e26394","DOI":"10.1002\/jia2.26394","volume":"27","author":"KA Christopoulos","year":"2024","unstructured":"Christopoulos KA, Smith MB, Pareek P, Dawdani A, Erguera XA, Dance KV, et al. Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir\/rilpivirine among early adopters in three U.S. clinics. J Int AIDS Soc. 2024;27(11):e26394. https:\/\/doi.org\/10.1002\/jia2.26394.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"5311_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qualitative Res Psychol"},{"issue":"4","key":"5311_CR5","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","volume":"8","author":"C Orkin","year":"2021","unstructured":"Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8(4):e185\u201396. https:\/\/doi.org\/10.1016\/S2352-3018(20)30340-4.","journal-title":"Lancet HIV"},{"issue":"12","key":"5311_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masi\u00e1 M, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020;382(12):1112\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1904398.","journal-title":"N Engl J Med"},{"issue":"10267","key":"5311_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2020","unstructured":"Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2020;396(10267):1994\u20132005. https:\/\/doi.org\/10.1016\/S0140-6736(20)32666-0.","journal-title":"Lancet"},{"key":"5311_CR8","doi-asserted-by":"publisher","unstructured":"O\u2019Shea J, Derton A, Henson J, Iqbal K, Briggs-Hagen M, Kourtis AP et al. Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir\/rilpivirine in the United States, 2021\u20132023. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2026 Feb 26. https:\/\/doi.org\/10.1097\/QAI.0000000000003855","DOI":"10.1097\/QAI.0000000000003855"},{"key":"5311_CR9","doi-asserted-by":"publisher","unstructured":"Troya J, Mican R, Galindo MJ, Bisbal O, Romero L, Torralba M et al. Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real\u2010world outcomes from the RELATIVITY cohort. HIV Medicine. 2026;hiv.70196. https:\/\/doi.org\/10.1111\/hiv.70196","DOI":"10.1111\/hiv.70196"},{"key":"5311_CR10","doi-asserted-by":"publisher","unstructured":"Rueda S, Park-Wyllie LY, Bayoumi A, Tynan AM, Antoniou T, Rourke S et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV\/AIDS. Cochrane HIV\/AIDS Group, editor. Cochrane Database of Systematic Reviews. 2006 Jul 19. https:\/\/doi.org\/10.1002\/14651858.CD001442.pub2","DOI":"10.1002\/14651858.CD001442.pub2"},{"issue":"6","key":"5311_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11908-008-0083-y","volume":"10","author":"JM Simoni","year":"2008","unstructured":"Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: A review of the literature. Curr Infect Dis Rep. 2008;10(6):515\u201321. https:\/\/doi.org\/10.1007\/s11908-008-0083-y.","journal-title":"Curr Infect Dis Rep"},{"issue":"5","key":"5311_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1007\/s10461-024-04610-w","volume":"29","author":"B Hunt","year":"2025","unstructured":"Hunt B, Pham A, Glick N, Sam S, Ni K, Meyers K, et al. A Universal Approach to Educating Patients with HIV about Long-Acting Injectable Treatment for HIV. AIDS Behav. 2025;29(5):1704\u201312. https:\/\/doi.org\/10.1007\/s10461-024-04610-w.","journal-title":"AIDS Behav"},{"issue":"1","key":"5311_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12913-021-06214-9","volume":"21","author":"A Mantsios","year":"2021","unstructured":"Mantsios A, Murray M, Karver TS, Davis W, Galai N, Kumar P, et al. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. BMC Health Serv Res. 2021;21(1):255. https:\/\/doi.org\/10.1186\/s12913-021-06214-9.","journal-title":"BMC Health Serv Res"},{"issue":"S1","key":"5311_CR14","doi-asserted-by":"publisher","first-page":"e26282","DOI":"10.1002\/jia2.26282","volume":"27","author":"N Nguyen","year":"2024","unstructured":"Nguyen N, Lane B, Golub SA, Chastain C, Zucker J, King K, et al. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project. J Int AIDS Soc. 2024;27(S1):e26282. https:\/\/doi.org\/10.1002\/jia2.26282.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"5311_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/j.pain.0000000000003096","volume":"165","author":"U Bingel","year":"2024","unstructured":"Bingel U, Wiech K. Informing about side effects: putting patients (preferences) first. Pain. 2024;165(2):252\u20133. https:\/\/doi.org\/10.1097\/j.pain.0000000000003096.","journal-title":"Pain"},{"issue":"4","key":"5311_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s10461-017-1871-x","volume":"22","author":"K Meyers","year":"2018","unstructured":"Meyers K, Rodriguez K, Brill AL, Wu Y, La Mar M, Dunbar D, et al. Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. AIDS Behav. 2018;22(4):1209\u201316. https:\/\/doi.org\/10.1007\/s10461-017-1871-x.","journal-title":"AIDS Behav"},{"issue":"1","key":"5311_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/hiv.13709","volume":"26","author":"KL McCall","year":"2025","unstructured":"McCall KL, Cabral DL, Coghlan JF, Concepcion AM, Denimarck KE, Shalumov SS. Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024. HIV Med. 2025;26(1):173\u20138. https:\/\/doi.org\/10.1111\/hiv.13709.","journal-title":"HIV Med"},{"issue":"6","key":"5311_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1525-1497.2006.00399.x","volume":"21","author":"MC Beach","year":"2006","unstructured":"Beach MC, Keruly J, Moore RD. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med. 2006;21(6):661\u20135. https:\/\/doi.org\/10.1111\/j.1525-1497.2006.00399.x.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"5311_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/QAI.0b013e318295b86a","volume":"63","author":"TE Flickinger","year":"2013","unstructured":"Flickinger TE, Saha S, Moore RD, Beach MC. Higher Quality Communication and Relationships Are Associated With Improved Patient Engagement in HIV Care. JAIDS J Acquir Immune Defic Syndr. 2013;63(3):362\u20136. https:\/\/doi.org\/10.1097\/QAI.0b013e318295b86a.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"11","key":"5311_CR20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1525-1497.2004.30418.x","volume":"19","author":"J Schneider","year":"2004","unstructured":"Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004;19(11):1096\u2013103. https:\/\/doi.org\/10.1111\/j.1525-1497.2004.30418.x.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"5311_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jana.2018.01.001","volume":"29","author":"J Jaiswal","year":"2018","unstructured":"Jaiswal J, Griffin-Tomas M, Singer SN, Lekas HM. Desire for Patient-Centered HIV Care Among Inconsistently Engaged Racial and Ethnic Minority People Living With HIV. J Assoc Nurses AIDS Care. 2018;29(3):426\u201338. https:\/\/doi.org\/10.1016\/j.jana.2018.01.001.","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"4","key":"5311_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/cid\/ciae265","volume":"79","author":"L Balter","year":"2024","unstructured":"Infectious Diseases Society of America (IDSA), Balter L, Beieler AM, Burdette SD, Chakraborty R, Ashley ED, et al. Position of the Infectious Diseases Society of America and the HIV Medicine Association on Team-based Infectious Diseases Care and the Roles of Advanced Practice Providers and Clinical Pharmacists. Clin Infect Dis. 2024;79(4):807\u20139. https:\/\/doi.org\/10.1093\/cid\/ciae265.","journal-title":"Clin Infect Dis"},{"key":"5311_CR23","doi-asserted-by":"publisher","first-page":"e56892","DOI":"10.2196\/56892","volume":"13","author":"MK Irvine","year":"2024","unstructured":"Irvine MK, Zimba R, Avoundjian T, Peterson M, Emmert C, Kulkarni SG, et al. Patient Education and Decision Support for Long-Acting Injectable HIV Antiretroviral Therapy: Protocol for Tool Development and Pilot Testing with Ryan White HIV\/AIDS Program Medical Case Management Programs in New York. JMIR Res Protoc. 2024;13:e56892. https:\/\/doi.org\/10.2196\/56892.","journal-title":"JMIR Res Protoc"},{"issue":"11","key":"5311_CR24","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1007\/s10461-019-02634-1","volume":"23","author":"MH Kim","year":"2019","unstructured":"Kim MH, Ahmed S, Tembo T, Sabelli R, Flick R, Yu X, et al. VITAL Start: Video-Based Intervention to Inspire Treatment Adherence for Life\u2014Pilot of a Novel Video-Based Approach to HIV Counseling for Pregnant Women Living with HIV. AIDS Behav. 2019;23(11):3140\u201351. https:\/\/doi.org\/10.1007\/s10461-019-02634-1.","journal-title":"AIDS Behav"},{"issue":"1","key":"5311_CR25","first-page":"34","volume":"12","author":"H Kremer","year":"2007","unstructured":"Kremer H, Ironson G. People living with HIV: sources of information on antiretroviral treatment and preferences for involvement in treatment decision-making. Eur J Med Res. 2007;12(1):34\u201342. PubMed PMID: 17363356.","journal-title":"Eur J Med Res"},{"key":"5311_CR26","doi-asserted-by":"publisher","unstructured":"Berg RC, Page S, \u00d8g\u00e5rd-Rep\u00e5l A. The effectiveness of peer-support for people living with HIV: A systematic review and meta-analysis. Mathes T, editor. PLoS ONE. 2021;16(6):e0252623. https:\/\/doi.org\/10.1371\/journal.pone.0252623","DOI":"10.1371\/journal.pone.0252623"},{"issue":"9","key":"5311_CR27","doi-asserted-by":"publisher","first-page":"e35646","DOI":"10.2196\/35646","volume":"11","author":"MM Philbin","year":"2022","unstructured":"Philbin MM, McCrimmon T, Shaffer VA, Kerrigan D, Pereyra M, Cohen MH, et al. A Patient Decision Aid (i.ARTs) to Facilitate Women\u2019s Choice Between Oral and Long-Acting Injectable Antiretroviral Treatment for HIV: Protocols for its Development and Randomized Controlled Pilot Trial. JMIR Res Protoc. 2022;11(9):e35646. https:\/\/doi.org\/10.2196\/35646.","journal-title":"JMIR Res Protoc"},{"issue":"10","key":"5311_CR28","doi-asserted-by":"publisher","first-page":"ofaf600","DOI":"10.1093\/ofid\/ofaf600","volume":"12","author":"KA Christopoulos","year":"2025","unstructured":"Christopoulos KA, Erguera X, Grochowski J, Hickey M, Imbert E, Dilworth S, et al. Discontinuation of Long-acting Injectable Cabotegravir\u2013Rilpivirine in a Large Clinic Cohort. Open Forum Infect Dis. 2025;12(10):ofaf600. https:\/\/doi.org\/10.1093\/ofid\/ofaf600.","journal-title":"Open Forum Infect Dis"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05311-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05311-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05311-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:52:15Z","timestamp":1791474735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05311-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":28,"alternative-id":["5311"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05311-2","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"12 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Moira McNulty reports serving on an advisory board for Gilead Sciences. Katerina Christopoulos reports having been a workshop participant for Janssen. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}